ASH 2022 | MagnetisMM-1: investigating the efficacy of elranatamab in patients with R/R multiple myeloma

This meeting has been really exciting because of the fact that we have a lot of bispecifics so, I presented the MagnetisMM-1 data, which was the first in human study using elranatamab in relapsed/refractory myeloma.

Elran is a bispecific T-cell engager, targeting BCMA, activating T-cells as well. And what we presented was data on 55 patients. Once they’d reached a dose, which has been used in the Phase II recommended dose.

What we found here was, in these 55 patients, a pretty high response rate. These were extremely heavily pretreated with a median line of five lines of treatment. They’d all seen a PI and IMId and a CD38 antibody. And the interesting thing about MagnetisMM-1 was we allowed for prior BCMA, so we had about 22% of these patients would had prior BCMA. It could have been a CAR T-cell or it could have been an antibody-drug conjugate.

Overall, the response rate in this 55 patient cohort was about 62%. And we did see responses even in patients who had prior BCMA, albeit a little bit lower, it was about 54%. And we saw that the duration of response in the responders was about 17 months with a CR and a complete CR rate, a stringent CR rate of approximately 38%. And a lot of these patients who achieved a stringent CR were MRD-negative, when we tested for MRD negativity.

This translated into a progression-free survival of close to 11.5 months, which is quite remarkable in this heavily pre-treated patients. Toxicity wise, extremely well tolerated. The expected toxicity of CRS was seen. Most of the CRS was grade one and grade two, and easy to manage and most of the other toxicities were hematologic, but easy to manage with supportive care.